MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Compromising Distance Vision Safety Profile Consistent With Previous Clinical Trials And No Treatment-Related Serious Adverse Events Reported In This StudyTargeting Application To U.S. FDA In Second Half of 2025PITTSBURGH, June 26, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from VEGA-3, the second pivotal Pha ...

PITTSBURGH, June 12, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About Viatris Viatris Inc.  ...

公司表现 - 基础业务表现强劲 已连续8或9个季度实现运营收入增长 [2] - 新产品收入超出最初指引 执行情况良好 [2] - 运营管理存在部分问题 涉及Indoor工厂的生产问题 [2] 资本分配 - 执行资本配置战略 包括支付股息和股票回购 [3] - 目前已回购略超3亿美元的股票 [3] 管理层动态 - 高管团队集体出席高盛医疗会议 显示公司当前阶段重要性 [1][2] - 参会高管包括CEO、CFO、首席商务官和研发负责人 [1]

Viatris (VTRS) FY Conference June 09, 2025 10:40 AM ET Speaker0 You good? Here we go. Speaker1 Great. Well, thank you everyone for joining us. We're very pleased to have Beatrice today. And with us, we have Scott Smith, CEO Doretta Mistras, Chief Financial Officer Corinne Lagoff, Chief Commercial Officer and Philippe Martin, Head of R and D. Maybe, Scott, before I jump into questions, I'll just hand it over to you to kind of make some opening remarks and then kind of frame the current year. Speaker2 First o ...

Viatris Inc. (NASDAQ:VTRS) Jefferies Global Healthcare Conference June 5, 2025 8:10 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Theodora Mistras - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Yuchen Ding Good morning, and welcome to the day 2 of the Jefferies Healthcare Conference. My name is Dennis Ding, spec pharma analyst here at Jefferies. I have the great pleasure of having the Viatris here, the CFO, Doretta and the CMO ...

Viatris公司集体诉讼案 - 诉讼指控公司在2024年8月8日至2025年2月26日期间发布重大虚假或误导性声明 未披露印度Indore工厂FDA检查失败的实际影响 包括关键产品来那度胺无法生产及运输受阻 导致2025财年财务预期远高于公司声称的"轻微阻力"[2] - 公司未能成功说服FDA将相关药物列入豁免清单 且该工厂问题对其他地区的产品运输也产生连锁影响[2] Canopy Growth公司集体诉讼案 - 诉讼涉及2024年5月30日至2025年2月6日期间 公司未披露加拿大Claybourne预卷产品的高生产成本及Storz & Bickel雾化设备的间接成本 这些成本对毛利率和整体财务表现造成重大负面影响[3] - 公司被指控夸大成本削减措施效果 同时淡化毛利率问题 导致关于业务前景的积极陈述缺乏合理依据[3]

公司诉讼事件 - 律师事务所Faruqi & Faruqi正在调查Viatris公司涉嫌违反联邦证券法的行为 包括发布虚假或误导性声明以及未披露关键风险信息 [2][4] - 诉讼指控公司低估了FDA对Indore工厂检查失败及警告信的影响 导致关键产品Lenalidomide无法生产运输 并对2025财年财务造成重大冲击 [4] - 公司2025年2月27日公布的2024年第四季度及全年财报中 将低于预期的2025年指引归因于Indore工厂警告信和进口禁令的财务影响 [5] 股价影响 - 公司股价在2025年2月26日至27日期间从每股11.24美元暴跌至9.53美元 单日跌幅达15.21% [6] 法律程序 - 联邦证券集体诉讼的牵头原告申请截止日期为2025年6月3日 牵头原告需是索赔金额最大且能代表集体成员的投资者 [2][7] - 律师事务所呼吁在2024年8月8日至2025年2月26日期间买入Viatris证券的投资者联系他们讨论法律权利 [1][8]

PHILADELPHIA, June 2, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Viatris securities during the Class Period may, no later than JUNE 3, 2025, seek to be appointed as a lead plaintiff representative ...

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc. Investors have until June 3, 2025, to ask the Court to be appointed to lead the case ...

案件背景 - 律师事务所提醒在2024年8月8日至2025年2月26日期间购买Viatris公司证券的投资者注意2025年6月3日的首席原告截止日期 [1] - 已针对Viatris提起集体诉讼，投资者可通过指定链接或联系方式加入诉讼 [2][6] 诉讼原因 - 公司被指控在印度Indore工厂未能通过FDA检查后向投资者隐瞒关键信息，包括FDA发出的警告信和进口禁令 [4] - 公司未披露检查具体时间、补救措施持续时间以及财务影响，同时将警告信的影响轻描淡写为"轻微阻力" [4][5] - 公司未说明哪些产品受警告信限制、哪些豁免，以及受限产品对公司当前财务和未来预测的重要性 [5] 公司行为影响 - 公司发布虚假或误导性声明，导致投资者以虚高价格购买证券，真相曝光后投资者遭受损失 [5] 律师事务所资质 - 该律所在证券集体诉讼领域有丰富经验，2017年因和解案件数量排名第一，2013年起每年位列前四 [3] - 2019年为投资者追回4.38亿美元，创始合伙人曾获法律行业荣誉 [3]